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Abstract
 
Endothelial cells (ECs) are believed to be an important component in the protection from
lipopolysaccharide (LPS)-induced endotoxic shock. However, the cellular and molecular mech-
anism is not well defined. Here, we report that signal transducer and activator of transcription
(STAT) 3 is an essential regulator of the antiinflammatory function of ECs in systemic immunity.
Because STAT3 deficiency results in early embryonic lethality, we have generated mice with a
conditional STAT3 deletion in endothelium (STAT3
 
E
 
 
 
/
 
 
 
). STAT3
 
E
 
 
 
/
 
 
 
 mice are healthy and
fertile, and isolated ECs initiate normal tube formation in vitro. Conditional endothelial but not
organ-specific (i.e., hepatocyte or cardiomyocyte) STAT3 knockout mice show an increased
susceptibility to lethality after LPS challenge. The LPS response in STAT3
 
E
 
 
 
/
 
 
 
 mice shows
exaggerated inflammation and leukocyte infiltration in multiple organs combined with elevated
activity of serum alanine aminotransferase and aspartate aminotransferase, indicating organ damage.
Concomitantly, proinflammatory cytokines are produced at an exaggerated level and for a
prolonged period. This defect cannot be explained by lack of antiinflammatory cytokines, such
as interleukin 10 and transforming growth factor 
 
 
 
. Instead, we have shown that a soluble activity
derived from endothelia and dependent on STAT3 is critical for suppression of interferon 
 
 
 
.
These data define STAT3 signaling within endothelia as a critical antiinflammatory mediator and
provide new insight to the protective function of ECs in inflammation.
Key words: transcription factors • Toll-like receptor • cytokines • transgenic/knockout • 
endotoxin shock
 
Introduction
 
Endothelial cells (ECs) provide a large surface area and
close contact for pathogens, and compose the interface
between hematopoietic cells and organs, mediating various
pathological processes. The physiological effects of the
immune system and cytokines on ECs have been well doc-
umented (1). However, whether ECs are active or passive
participants in this process is less well characterized. Both
human and murine ECs have been shown to participate in
immune recognition by expressing MHC and costimulatory
molecules (2, 3), suggesting that they act as antigen-presenting
cells. It has been further suggested that ECs would provide
signals for immune modulation via cell surface or secreted
factors (4), raising the prospect that intracellular signaling in
ECs could be manipulated to affect immune responses.
The Janus kinase signal transducer and activator of tran-
scription (STAT) signaling pathway is activated by a diverse
array of cytokines and growth factors, and has been implicated
in a variety of cellular functions, including inflammatory
processes (5). Ligand binding induces receptor dimerization
and tyrosine phosphoryalation of receptor-associated Janus
kinases, followed by activation of specific STATs. Phos-
phorylated and dimerized STATs translocate to the nucleus
to activate the transcription of target genes. STAT3 is the
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molecule 1; STAT, signal transducer and activator of transcription; TLR,
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mediator of many early response genes activated by IL-6
family cytokines (6, 7). The zygotic STAT3 deletion is le-
thal before gastrulation (8); therefore, we generated mice
with a conditional STAT3 allele (9).
Various cell type–specific STAT3 KOs have been estab-
lished, including keratinocytes (10), T cells (11), or macro-
phages/neutrophils (12). STAT3 deletion in mice within the
macrophage/neutrophil lineage results in chronic inflamma-
tion and pathological colitis due to enhanced IFN-
 
 
 
–pro-
ducing T cells (12). These mice have an overabundance of
proinflammatory cytokines due to a defect in signaling by
IL-10, a major antiinflammatory cytokine that requires
STAT3 (13). IL-10 KO mice (14) show a similar phenotype
as the STAT3 macrophage/neutrophil KO mice, although
IL-10 levels are increased in these STAT3-deficient mice
(12). We have also shown recently that removal of STAT3
from hematopoietic progenitors results in increased proin-
flammatory cytokine production, inflammatory bowel dis-
ease, and an expanded macrophage population (9). These
genetic ablation studies have shown that STAT3 plays a crit-
ical role in controlling inflammation as the deletion of
STAT3 causes an exacerbated inflammatory response.
The antiinflammatory role of STAT3 is, at least in part,
due to the antagonism of STAT1 (15) and inducing genes
that inhibit the receptor (e.g., suppressor of cytokine sig-
naling; references 16, 17). Alternative forms of STAT3
have been shown to antagonize inflammatory signaling.
STAT3
 
 
 
 is an alternatively spliced transcript of STAT3
that lacks the transactivation domain. When STAT3
 
 
 
 is
knocked out by removal of a cryptic splice site, the animals
become sensitive to LPS-induced endotoxic shock (18).
The role of STAT3 in directing an antiinflammatory re-
sponse is clearly defined within immune cells, but less well
understood within other cell types, such as endothelia.
We investigated the role of STAT3 cytokine signaling
within endothelium to better understand the role that ECs
play in inflammation. Innate inflammatory signaling can be
initiated through Toll-like receptors (TLRs). TLRs re-
spond to a set of natural pathogenic ligands and induce a
primary immune response using the NF-
 
 
 
B Rel family,
c-Jun NH
 
2
 
-terminal kinase, phosphatidylinositol 3 kinase,
p38, and ERK pathways (19). This primary response leads
to a secondary response through type I IFNs that can acti-
vate several STAT family members (19–21). LPS from
gram-negative bacteria is a potent TLR4 ligand and elicits a
strong inflammatory response and a characteristic cytokine
burst. The response to LPS is generally self limited at least
in part through the actions of IL-10. Activation of the in-
nate immune response to LPS is a measure of the immuno-
logical health of an animal. We have generated an endothe-
lial conditional KO of STAT3. Here, we show that
endothelial STAT3 signaling plays a critical antiinflamma-
tory role in LPS-induced endotoxic shock by controlling
subsequent cytokine-induced tissue damage and lethality.
Furthermore, we show that a soluble factor that is depen-
dent on STAT3 plays a critical role in the control of IFN-
 
 
 
production during LPS-induced inflammation.
 
Materials and Methods
 
Animals.
 
Generation of mice with a conditional STAT3 allele
has been described previously (9). Exons 18–20, which contain
the SH2 domain of STAT3, were flanked by two loxP sites. Two
Tie2-Cre transgenic mouse strains expressing Cre under the con-
trol of the TIE2–kinase promoter/enhancer were generated. One
was described previously with expression in hematopoietic and
ECs (14, 22), and here, we describe another with a more endo-
thelial-specific expression. The TIE2e-Cre;STAT3
 
f/d
 
 mutant
mice were generated through TIE2e-Cre;STAT3
 
 
 
/d
 
 mice crossed
to STAT3
 
f/f
 
 mice. The genotype was determined by PCR as de-
scribed previously (9). TIE2e-Cre mice were mated with Z/EG
reporter mice, which produce green fluorescence protein (GFP)
from a constitutive promoter after removal of LacZ by cre-medi-
ated recombination (23). Transthyretin (TTR) Cre mice were
generated in our laboratory (unpublished data) and the 
 
 
 
-MHC-
Cre mice were from M. Schneider (Baylor College of Medicine,
Houston, TX). All procedures were performed in accordance
with the National Institutes of Health Guide for the Care and Use
of Laboratory Animals and under the approval of the Yale Medi-
cal School Animal Care and Use Committee.
 
EC Isolation and Flow Cytometry.
 
Liver sinusoidal ECs
(LSECs) were isolated through a modified method (24). Livers
were perfused through the portal vein with HBSS with 0.5 mM
EGTA briefly and subsequently digested with 0.015% collagenase
II and IV (GIBCO BRL) solution. Excised liver was minced and
further digested in collagenase solution at 37
 
 
 
C for 30 min. Hepa-
tocytes were removed by brief centrifugation twice at 50 
 
g
 
. The
supernatant was collected and centrifuged at 350 
 
g
 
 for 5 min. The
pellet was resuspended in 30% Percoll-HBSS and loaded on 50%
Percoll-HBSS. The density gradient column was centrifuged at
900 
 
g
 
 for 30 min. The cell layer from 30 to 50% Percoll-HBSS was
collected. This layer contained an enriched fraction of liver ECs.
For further purification, enriched LSECs were blocked with
anti-FCR antibody and 5% FCS-PBS, and incubated with anti-
CD144 (VE-cadherin) antibody conjugated with R-phycoerythrin
(BD Biosciences). Stained cells were sorted on a FACSCalibur™
using CELLQuest™ software (Becton Dickinson). A similar pro-
cedure was used in analyzing GFP
 
 
 
 bone marrow and splenocytes.
 
Tube Formation Assay.
 
To compare the tube forming ability
of control and mutant ECs, cells were plated on a thin layer of
Matrigel (Becton Dickinson) at 2 
 
 
 
 10
 
5
 
 cells/well of a 24-well
plate in 10% FCS DMEM and allowed to form a tubular structure
for overnight. Cells were assessed on their ability to form simple
tube structures and their morphology.
 
Western Blotting.
 
Tissues were washed briefly with PBS and
lysed with radioimmunoprecipitation (10 mM Tris-HCl, pH 7.4,
1% NP-40, 0.1% sodium deoxycholate, 0.1% sodium dodecyl
sulfate, 150 mM sodium chloride, 1 mM ethylendiamintetraacetic
acid, 100 mM sodium fluoride, 200 
 
 
 
M sodium orthovanadate,
0.5 mM phenylmethanesulfonyl fluoride, 2 
 
 
 
g/ml aprotinin, 1
 
 
 
g/ml luepeptin, and 1 
 
 
 
g/ml pepstatin). The cell lysates were
centrifuged, and the supernatants were removed and assayed for
protein content using the bicinchoninic acid protein assay kit
(Pierce Chemical Co.). Cell lysates were separated on SDS-
PAGEs, transferred to polyvinylidene difluoride membranes, and
incubated with antiphospho-specific (Tyr705) STAT3 (New En-
gland Biolabs, Inc.), STAT3, and STAT1 (Santa Cruz Biotech-
nology, Inc.) antibodies. Anti–rabbit antibody conjugated with
horseradish peroxidase was used as secondary antibody, and visu-
alized using chemiluminescent substrate (SuperSignal; Pierce
Chemical Co.).T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
Kano et al.
 
1519
 
LPS Challenge and Serum Chemistry.
 
Mice were given an in-
traperitoneal injection of 5 mg/kg LPS and had blood drawn or
were killed at indicated times. Serum activities of alanine
aminotransferase (ALT) and aspartate aminotransferase (AST)
were measured using a transaminase kit according to the manu-
facturer’s instructions (Sigma-Aldrich).
 
ELISA.
 
Serum or cell culture supernatant concentrations of
IL-4, -6, -10, TNF-
 
 
 
, active TGF-
 
 
 
, and IFN-
 
 
 
 were deter-
mined by ELISA according to the manufacturer’s instructions
(R&D Systems).
 
Histological Analysis.
 
Tissue was collected and fixed in 4%
paraformaldehyde for 4 h, infused with 9% sucrose for 4 h and 20%
sucrose overnight except for liver, which was fixed in ice-cold ace-
tone. Tissue was embedded in optimum cutting temperature, fro-
zen in liquid nitrogen, and stored at 
 
 
 
80 C
 
 
 
 until sectioning. 10-
 
 
 
M frozen sections were cut and washed in PBS, and GFP was
imaged by epifluorescence microscopy. Indirect immunofluores-
cence staining was done using a platelet-EC adhesion molecule 1
(PECAM-1)/CD31 antibody and rhodamine-conjugated second-
ary antibody. Alternatively, tissues were fixed in 4% paraformalde-
hyde and paraffin embedded. 6-
 
 
 
M tissue sections were stained
with hematoxylin and eosin using standard techniques.
 
Results
 
Endothelial-specific TIE2Cre Transgenic Line.
 
A line of
Cre recombinase–expressing transgenic mice was generated
using the TIE2 5
 
 
 
 promoter and first intron enhancer ele-
ment (Fig. 1 A; reference 22). When these were mated to
Z/EG reporter mice that express GFP after Cre-mediated
recombination, a widespread expression of GFP was ob-
served within endothelium of brain, heart, and liver (Fig.
 
1 B), among others. The GFP signal colocalized with CD31/
PECAM-1 immunostaining, indicating that GFP
 
 
 
 cells
were of endothelial origin (Fig. 1 B).
Because ECs are BM derived, we checked the expres-
sion of GFP in BM cells to determine the specificity of this
TIE2 transgene by flow cytometry. Approximately 1.5% of
the cells within BM were positive for GFP (Fig. 1 C).
These cells did not segregate into specific populations dur-
ing subsequent hematopoietic development as judged by
flow cytometry analysis of spleen cells (Fig. 1).
Next, we asked if the GFP were associated with any par-
ticular cell lineage, such as EC precursors or macrophages.
We sorted GFP
 
 
 
 cells with markers for PECAM-1, CD4,
CD8, CD44, CD86, Mac-1, and I-AB. No specific associ-
ation of GFP was seen with any of tested markers (un-
published data). This was supported by a microscopic
inspection that revealed that the GFP
 
 
 
 cells were morpho-
logically divergent. Consistently, the BM cell cultures un-
der different cytokines/growth factors, such as macrophage
colony–stimulating factor, G–macrophage colony–stimu-
lating factor, granulocyte stimulating factor, vascular endo-
thelial growth factor, and basic fibroblast growth factor,
were not populated with GFP
 
 
 
 cells to any particular cell
lineage. We conclude that the expression of Cre in this
strain of TIE2-Cre mice is restricted to endothelium, and
Cre expression is minimally leaky. Therefore, we desig-
nated the transgene as TIE2e-Cre.
 
STAT3-deficient ECs Appear Physiologically Normal.
 
We
crossed the TIE2e-Cre line (C57/BL/6) to the C57/BL/6
mice with a LoxP-targeted disruption in the SH2 do-
Figure 1. Endothelial-specific Cre recombinase. (A) A line of Cre recombinase expressing transgenic mice was generated using the TIE2 5  promoter
and first intron enhancer element. (B) TIE2e-Cre mice were mated to Z/EG reporter mice. Animals were killed, tissue was frozen, and 10 micrometer
sections were made. Sections from brain, heart, and liver are shown. Arrow indicates colocalization with CD31/PECAM-1. (C) Flow cytometry of bone
marrow and splenotcytes show that  1.5% of cells express GFP, indicating that the expression of Cre recombinase is mainly restricted to ECs.T
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main of STAT3 to obtain TIE2e-Cre;STAT3
 
f/d
 
 mice
(STAT3
 
E
 
 
 
/
 
 
 
). The deletion results in the loss of the
COOH terminus and renders STAT3 transcriptionally in-
active. To confirm the KO biochemically, we analyzed
LSECs from STAT3
 
E
 
 
 
/
 
 
 
 mice and their littermates
(TIE2e-Cre;STAT3
 
f/
 
 
 
) along with other tissues. Western
blot results showed that STAT3 protein was greatly re-
duced in the KO ECs, whereas STAT1 was unaffected
(Fig. 2, A and B). The residual STAT3 in the preparation
reflects the contamination of other cell types due to LSEC
isolation procedure (see Fig. 5 A). As expected, STAT3
was not deleted in hepatocytes, peritoneal macrophages,
nor T or B cells (Fig. 2 A). Thus, the deletion of STAT3 in
ECs is specific and effective.
Mice with a targeted disruption of endothelial STAT3
were born at the expected Mendelian ratio, survived
through adulthood, and were fertile, indicating normal de-
velopmental angiogenesis. Tube formation on Matrigel is a
widely used in vitro assay for a well-defined characteristic
 
of ECs. Isolated LSECs from KOs and controls were
assayed for their ability to undergo tube formations on
Matrigel. ECs with both genetic backgrounds formed tube
structures and we were unable to distinguish differences
between groups (Fig. 2 C).
 
Endothelial STAT3 Protects against Endotoxic Shock.
 
We
asked if mutant mice had normal innate immune function.
To test this, we injected STAT3
 
E
 
 
 
/
 
 
 
 mice with 5 mg/kg
LPS (026:B6 serotype). LPS elicits strong innate immune
responses via TLR4 (25, 26) and has a characteristic cyto-
kine response. In STAT3
 
E
 
 
 
/
 
 
 
 mice, this response was exag-
gerated and induced lethality (Fig. 2, E and F). The lethality
was evident 
 
 
 
17 h after LPS administration. By 40 h, 60%
of STAT3
 
E
 
 
 
/
 
 
 
 mice had died, whereas all of the heterozy-
gous littermates survived. To test if other STAT3 KO lines
were susceptible to lethality at this dose, mice from car-
diomyocyte-specific 
 
 
 
MHC-Cre;STAT3
 
f/d
 
 (STAT3
 
H
 
 
 
/
 
 
 
)
and hepatocyte-specific TTR-Cre;STAT3
 
f/d
 
 (STAT3
 
L
 
 
 
/
 
 
 
)
STAT3-deleted mice were subjected to LPS challenge.
Figure 2. Endothelial STAT3
deletion and endotoxin-induced
lethality. (A) Peritoneal macro-
phages (p-Mac), T cells, B cells,
and hepatocytes were isolated
from WT and KO mice and total
protein was extracted. SDS-PAGE
fractionation and Western blot-
ting using a STAT3-specific poly-
clonal antibody showed robust
expression of STAT3 within these
cell types. Total STAT1 expres-
sion was also unaltered. (B)
Isolated ECs from TIE2e-Cre;
STAT3f/d, and TIE2e-Cre;STAT3f/ 
mice were stimulated with IL-6.
Western blot analysis of phospho-
specific STAT3 revealed signifi-
cantly reduced phosphorylated
STAT3 in conditional KOs. The
membranes were stripped and re-
blotted with antibodies to STAT3
and STAT1. (C) STAT3 null and
wild-type ECs were isolated and
plated on Matrigel. Both geno-
types formed normal tube struc-
tures in vitro, and no differences
could be found between groups.
(D) Peritoneal macrophages were
isolated, stimulated with LPS, and
assayed for TNF- . There was no
change in the production of
TNF- , indicating a normal
response by macrophages. (E)
TIE2e-Cre;STAT3f/d and TIE2e-
Cre;STAT3f/  mice were given
an intraperitoneal dose of 5 mg/kg
LPS. 60% of TIE2e-Cre;STAT3f/d
mice died, whereas all wild-type
littermates survived. Lethality was
initiated after 16 h. Both cardio-
myocyte ( MHC-Cre;STAT3f/f
(F) and hepatocyte (TTR-Cre;
STAT3f/f) STAT3 conditional
KO (G) mice were tested for LPS-
induced lethality.T
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Both STAT3
 
H
 
 
 
/
 
 
 
 and STAT3
 
L
 
 
 
/
 
 
 
 mice were not suscepti-
ble to endotoxic shock–mediated lethality at this dose, sug-
gesting that ECs play a role in this susceptibility.
STAT3 is known to be important for normal signaling of
many cytokines. Removal of STAT3 within cells of the
immune system, such as macrophages and neutrophils, re-
sults in an exaggerated inflammatory cytokine response
and Th1 polarization (12). However, loss of endothelial
STAT3 causes a similar, albeit less severe, phenotype as the
macrophage KO even though there is normal STAT3 ex-
pression within hematopoietic cells. This is a rather surpris-
ing finding. To rule out the possibility that the deletion of
STAT3 in a limited set of macrophages interfered with the
phenotypical readout of STAT3
 
E
 
 
 
/
 
 
 
 mice, we assayed
TNF-
 
 
 
 production in isolated peritoneal macrophages
from both mutants and controls (Fig. 2 D). Unlike STAT3-
deficient macrophages, which exhibit increased TNF-
 
 
 
expression in response to LPS (12), the macrophages from
STAT3
 
E
 
 
 
/
 
 
 
 mice behaved identically to controls, suggest-
ing that the deletion of STAT3 in bone marrow cells in
STAT3
 
E
 
 
 
/
 
 
 
 mice did not alter the function of the macro-
phages.
 
LPS Induces Severe Systemic Inflammation in STAT3
 
E
 
 / 
Mice. Upon histological examination of STAT3E /  mice
17 h after LPS injection, mice had severe infiltration of leu-
kocytes into multiple organs, including the liver (Fig. 3 A)
as well as lung and gut (not depicted). We focused on liver
pathology as a primary target organ. In the liver, the portal
vein area was the most severely affected because leukocytes
could be seen invading and accumulating under endothelia
around the portal veins. In contrast, individual organs such
as the heart in STAT3H /  and the liver in STAT3L /  (not
depicted) as well as in control mice did not show obvious
infiltration of leukocytes (Fig. 3 A), suggesting a role for en-
dothelial STAT3 in controlling the influx of leukocytes.
To further evaluate the systemic effect of LPS on
STAT3E /  mice, we measured the serum levels of ALT
and AST. Serum ALT is an indicator of liver damage,
whereas AST is expressed in numerous organs, including
liver, heart, skeletal muscle, kidney, brain, and pancreas.
Therefore, it is an indicator of multiorgan damage (27).
The ALT and AST activities in serum were increased at
comparable levels in both STAT3E /  and control mice
initially (8 h after LPS challenge). By 17 h, the ALT and
AST levels were reduced or remained at low in the control
mice, but both ALT (P   0.05) and AST (P   0.01) levels
further increased in STAT3E /  mice (Fig. 3 B).
LPS Elicits an Exaggerated Cytokine Response in STAT3E / 
Mutants. To examine the immunological status and the
potential causes of lethality in these mice, we measured se-
rum levels of known inflammatory mediators. Serum was
taken at different time points after LPS treatment (Fig.
4).  The kinetics of cytokine induction were measured.
STAT3E /  mice exhibited significantly elevated inflam-
matory cytokines. TNF-  showed a rapid and significant
increase of fourfold as early as 1.5 h (P    0.05), but
dropped rapidly as expected. In STAT3E /  mice, the rise
of IL-6 was both exaggerated at 1.5 h (P   0.05) and pro-
longed at 17 h (P   0.05). As expected, IFN-  was delayed
in response to LPS challenge. It increased slightly at 8 h in
control animals. However, in STAT3E /  mice, IFN- 
levels were significantly increased by 7.5-fold at 8 h (P  
Figure 3. Endothelial STAT3 mutant mice
have liver and tissue damage after LPS adminis-
tration. (A) Tissue was collected at 0 and 17 h
after LPS administration and stained with hema-
toxylin and eosin. Leukocyte infiltration can be
seen in the liver of LPS-treated TIE2e-Cre;
STAT3f/d mice. Specifically, the portal vein had
the most severe leukocyte accumulation. TTR-
Cre;STAT3f/d and control mice do not show
severe infiltration. (B) Serum ALT and AST
activity was measured in TIE2e-Cre;STAT3f/d
and TIE2e-Cre;STAT3f/  mice. At 17 h, both
were higher in TIE2e-Cre;STAT3f/d mice than
controls (P   0.05).T
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0.05) and sustained through 17 h, a time when the controls
had no detectable level of IFN- .
Next, we asked if IL-10 production was compromised
in STAT3E /  mice, which could account for the exagger-
ated inflammatory phenotype induced by LPS, as IL-10 is a
potent antiinflammatory cytokine. Inconsistent with this
notion, STAT3E /  mice exhibited significantly increased
IL-10 levels after LPS treatment (P   0.05) and this was
sustained longer than in controls (Fig. 4). Because STAT3
signaling within immune cells is not compromised geneti-
cally in STAT3E /  mutants, the loss of antiinflammatory
cytokines in these animals cannot be explained by a block
of IL-10 signaling, a result that is different from the macro-
phage/neutrophil STAT3 KO reported previously (12).
Similarly, TGF-  and IL-4 levels were unchanged be-
tween control and KO (unpublished data). Together, these
data suggest a yet-undefined STAT3-dependent endothe-
lial factor that is able to regulate the expression of proin-
flammatory cytokines.
LSEC Inhibit IFN-  via a STAT3 Dependent Mechanism.
Our in vivo studies have demonstrated that STAT3 medi-
ates interplay between ECs and the immune system in sys-
temic immunity. To confirm the in vivo observation in a
simpler system, we studied the effect of isolated LSECs on
inflammatory cytokine production by leukocytes. By using
FACS® with a CD144 antibody, we were able to purify
LSECs to  98% (Fig. 5 A). At such purity, LPS did not in-
duce either IFN-  or TNF-  in ECs from either genetic
background (Fig. 5, B and C). In contrast, the purified
splenocytes responded to LPS with production of both
IFN-  and TNF- . These results indicate that it is the
splenocytes that were the primary LPS-responding and cy-
tokine-producing cells.
We tested the regulatory function of ECs on cytokine
production by splenocytes. Purified LSECs were incubated
with freshly isolated wild-type (C57BL/6) splenocytes with
1  g/ml LPS. Cytokine levels were assayed after 17 h of
coculture. A strong suppression of IFN-  production by
control LSECs was observed (Fig. 5 B). However, IFN- 
was not suppressed by STAT3E /  LSECs (Fig. 5 B). In
contrast, TNF-  induction was not affected by the LSEC
coculture (Fig. 5 C). Thus, STAT3 mediates its antiinflam-
matory effect, at least in part, by providing a signal to an-
tagonize IFN-  production.
LSEC Inhibit IFN-  through Soluble Factors. Next, we
asked if the suppressive effect of ECs on inflammation is
mediated through a soluble or cell surface molecule, as it
has been postulated that LSECs can suppress IFN-  from
Th1 cells via class II MHC (28). We incubated 10% endo-
thelial conditioned media with splenocytes under LPS
stimulation. The media from control ECs significantly re-
duced IFN-  production, whereas STAT3E /  media
could not (Fig. 5 D). TNF-  was minimally affected in
both media (Fig. 5 E).
Several control experiments indicated that the inhibitory
effects of conditioned media and LSECs on IFN-  produc-
tion are rather specific and STAT3 dependent. First,
STAT1 /  LSECs retained the ability to suppress IFN- 
production, whereas both KO and WT hepatocytes could
not, suggesting that both the molecular regulator and the
cellular origin of the suppressor are specific (unpublished
data). The suppression of the IFN-  production was potent
and dose dependent (Fig. 5 F). Again, the suppressive ef-
fects of conditioned media on TNF-  were minimal, and
did not follow the same pattern of IFN-  suppression.
These findings suggest that the effector is soluble, constitu-
tive, and dependent on STAT3, and showed a degree of
specificity to IFN- .
It is important to determine EC production of antiinflam-
matory cytokines such as IL-10 and TGF-  in our system
Figure 4. Serum cytokines have an exaggerated and
prolonged expression. Serum was collected from mutant
and wild-type animals after LPS treatment and measured
by ELISA at 0-, 1.5-, 8-, and 17-h time points (animals in
each group, n   4). Mutant TNF-  was significantly in-
creased by fourfold over controls at 1.5 h but was reduced
at 8 h. IL-10 had a similar pattern as TNF- , increasing by
twofold. In contrast, IFN-  was increased at 8 h (7.5-fold)
and remained high at 17 h, whereas IL-6 was increased at
1.5 and 17 h. Shaded bar, TIE2e-Cre;STAT3f/ . White
bar, TIE2e-Cre;STAT3f/d. ND, not detected. *, P   0.05.T
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because both molecules suppress the production of IFN- 
from splenocytes. We measured IL-10 from LSEC-condi-
tioned media from both control and STAT3E /  LSECs.
IL-10 is constitutively expressed in wild-type ECs. If IL-10
is the soluble effector, one would expect to see a reduction
of IL-10 levels in the media from STAT3E /  ECs. How-
ever, the IL-10 levels in wild-type and mutant LSEC-condi-
tioned mediums were equivalent (unpublished data). Simi-
larly, the TGF-  levels were unaffected by STAT3 deletion
(unpublished data). Evidently, there is a different IFN-  reg-
ulator produced by LSECs under the control of STAT3.
The nature of this suppressor is under investigation.
Figure 5. Endothelial suppression of
IFN-  is STAT3 dependent. (A) ECs were
isolated from the liver and purified by
FACS® sorting. STAT3 null and WT LSECs
were incubated with WT LPS-induced
splenocytes and assayed for IFN-  and
TNF- . (B) IFN-  was not detected (ND)
in cultures without splenocytes regardless of
LPS treatment or genetic background. IFN- 
was induced in splenocytes upon LPS treat-
ment and significantly reduced from spleno-
cytes cocultured with WT endothelium
(P   0.05). When STAT3 null LSECs were
cocultured with WT splenocytes, IFN- 
was not suppressed. (C) TNF-  was un-
changed between groups. (D and E) 10%
conditioned media from STAT3 null and
WT LSECs were incubated with LPS-
stimulated WT splenocytes and assayed for
IFN-  and TNF- . (D) IFN-  was signifi-
cantly reduced from splenocytes incubated
with 10% WT LSEC-conditioned media
(P   0.05). This suppression was released
when 10% STAT3 null LSECs condi-
tioned media was used. (E) TNF-  was
unchanged between groups. (B and C)
Shaded bar, without LPS. White bar, LPS
treatment. (F) Wild-type EC-conditioned
media at concentrations of 0%–20% were
incubated with LPS-stimulated splenocytes
and measured for IFN-  and TNF- , reveal-
ing a dose-dependent effect on IFN- .
ND, not detected.T
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Discussion
The interplay between ECs and the immune system is fun-
damental for systemic immunity. Here, we have shown that
ECs control LPS-induced toxicity by controlling the cyto-
kine response via STAT3. This demonstrates the importance
of ECs during endotoxic shock and underscores the impor-
tance of STAT3 in the control of systemic inflammation.
The KO of STAT3 is embryonically lethal at E6.5, and
the cause of lethality is not fully understood (8). STAT3 is
expressed early in embryonic postimplantation develop-
ment when angiogenesis is critical. We assume that STAT3
is not an essential angiogenic factor because STAT3 endo-
thelial conditional KOs are born at a normal Mendelian ra-
tio, and pups are healthy and indistinguishable from litter-
mates. Furthermore, in vitro assays for tube formation
show no obvious difference between control and STAT3
null ECs.
LPS elicits a strong and predictable immune response.
Therefore, we used LPS as an indicator of the immunolog-
ical vigor of these animals. Under threshold levels of LPS,
control mice survived, but 60% of STAT3E /  mice died
as a result of the treatment. These data are further validated
by the normal response of LPS in other conditional STAT3
KOs. We used both cardiomyocyte- and hepatocyte-spe-
cific STAT3 conditional KO strains. Although the endo-
thelial-specific strain had massive leukocyte infiltration into
the liver, the hepatocyte and cardiomyocyte conditional
KOs had a less severe phenotype. Analysis of macrophages
from STAT3E /  animals showed no contribution to the
phenotype, suggesting a specific role for ECs. This under-
scores the importance of endothelia in systemic inflamma-
tion and points to STAT3 as a central control molecule for
this inflammation.
Serum chemistry from LPS-challenged STAT3E /  mice
was consistent with hepatitis and other tissue damage as ev-
idenced by elevated activity of serum ALT and AST, hall-
marks of liver and systemic tissue damage respectively (27).
These data cumulatively show that LPS induces severe tis-
sue damage in the conditional KO.
We did not directly investigate the cause of lethality due
to LPS. However, we suspect the pro-inflammatory burst.
Although TNF-  and IL-6 were elevated significantly in
these animals, both are not the mediators of lethality as
shown by the genetic disruption of these cytokines. Re-
cently, a double KO of macrophage STAT3 and TNF- 
did not relieve the inflammatory bowel disease in these an-
imals. However, deletion of IL-12, a cytokine essential for
IFN-  production, did relieve the phenotype (29). Genetic
ablation of IFN-  or its receptor confers resistance to LPS-
mediated lethality. Together, these data with the increased
and prolonged expression of IFN-  in the endothelial
STAT3 KO strongly suggest a role for IFN-  in promoting
the LPS-induced lethality.
IL-10 is a strong immunosuppressant and is expressed in
endothelium. The significant increase of IL-10 in LPS-
treated STAT3E /  mice is puzzling because it would be
expected that such high levels of IL-10 would be adequate
to inhibit IFN-  expression. However, in the absence of
STAT3, suppressor of cytokine signaling 3 levels could be
reduced, resulting in higher IL-10 levels produced in ECs
(30). These data would suggest that there is another impor-
tant mediator of cytokine expression that is absent in
STAT3E /  mice.
We found that ECs could inhibit LPS-induced IFN- 
expression from splenocytes, and that STAT3E /  ECs
could not. IFN-  is a critical mediator of lethality during
endotoxin challenge (31). It has been postulated that class II
MHC present on LSECs could inhibit IFN-  production
by TH1 cells in vitro. Alternatively, our data suggest that a
soluble factor, dependent on STAT3, is present that can se-
lectively suppress the production of IFN-  from spleno-
cytes (Fig. 5, B–E). Our preliminary characterization sug-
gests that the factor is a large protein that differs in size
from known inhibitory cytokines (unpublished data).
The discovery of an endothelial-derived mediator of
suppression of systemic endotoxin shock and cytokine pro-
duction could be of clinical relevance. Whether ECs con-
trol the expression of IFN-  at the transcriptional level or if
they control differentiation and polarization of T cells has
not been determined. Because STAT3 has been shown to
regulate its expression in vivo and in vitro, one may be able
to modulate STAT3 signaling in patients exhibiting symp-
toms of bacterial shock to limit tissue damage.
We thank Dr. J. Madri for helpful discussions. 
R. Flavell is an investigator of the Howard Hughes Medical Insti-
tute and X.-Y. Fu was a recipient of a Career Development Award
from National Institutes of Health (NIH). This work is supported by
NIH grants AI34522 (to X.-Y. Fu) and HL51014 (to J.S. Pober).
Submitted: 17 January 2003
Accepted: 23 September 2003
References
1. Pober, J.S., and R.S. Cotran. 1990. The role of endothelial
cells in inflammation. Transplantation. 50:537–544.
2. Hughes, C.C., C.O. Savage, and J.S. Pober. 1990. The en-
dothelial cell as a regulator of T-cell function. Immunol. Rev.
117:85–102.
3. Lohse, A.W., P.A. Knolle, K. Bilo, A. Uhrig, C. Waldmann,
M. Ibe, E. Schmitt, G. Gerken, and K.H. Meyer Zum Busch-
enfelde. 1996. Antigen-presenting function and B7 expres-
sion of murine sinusoidal endothelial cells and Kupffer cells.
Gastroenterology. 110:1175–1181.
4. Limmer, A., J. Ohl, C. Kurts, H.G. Ljunggren, Y. Reiss, M.
Groettrup, F. Momburg, B. Arnold, and P.A. Knolle. 2000.
Efficient presentation of exogenous antigen by liver endothe-
lial cells to CD8  T cells results in antigen-specific T-cell
tolerance. Nat. Med. 6:1348–1354.
5. Leonard, W.J., and J.J. O’Shea. 1998. Jaks and STATs: bio-
logical implications. Annu. Rev. Immunol. 16:293–322.
6. Akira, S., Y. Nishio, M. Inoue, X.J. Wang, S. Wei, T. Mat-
susaka, K. Yoshida, T. Sudo, M. Naruto, and T. Kishimoto.
1994. Molecular cloning of APRF, a novel IFN-stimulated
gene factor 3 p91-related transcription factor involved in theT
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
Kano et al. 1525
gp130-mediated signaling pathway. Cell. 77:63–71.
7. Zhong, Z., Z. Wen, and J.E. Darnell, Jr. 1994. Stat3: a STAT
family member activated by tyrosine phosphorylation in re-
sponse to epidermal growth factor and interleukin-6. Science.
264:95–98.
8. Takeda, K., K. Noguchi, W. Shi, T. Tanaka, M. Matsumoto,
N. Yoshida, T. Kishimoto, and S. Akira. 1997. Targeted dis-
ruption of the mouse Stat3 gene leads to early embryonic le-
thality. Proc. Natl. Acad. Sci. USA. 94:3801–3804.
9. Welte, T., S.S.M. Zhang, T. Wang, Z. Zhang, A. Hesslein,
A. Yin, A. Kano, Y. Iwamoto, E. Li, J.E. Craft, et al. 2003.
STAT3 deletion during hematopoiesis causes Crohn’s dis-
ease-like pathogenesis and lethality, revealing a role of
STAT3 in regulation of innate immunity. Proc. Natl. Acad.
Sci. USA. 100:1879–1884. 
10. Sano, S., S. Itami, K. Takeda, M. Tarutani, Y. Yamaguchi,
H. Miura, K. Yoshikawa, S. Akira, and J. Takeda. 1999. Ke-
ratinocyte-specific ablation of Stat3 exhibits impaired skin re-
modeling, but does not affect skin morphogenesis. EMBO J.
18:4657–4668.
11. Takeda, K., T. Kaisho, N. Yoshida, J. Takeda, T. Kishimoto,
and S. Akira. 1998. Stat3 activation is responsible for IL-6-
dependent T cell proliferation through preventing apoptosis:
generation and characterization of T cell-specific Stat3-defi-
cient mice. J. Immunol. 161:4652–4660.
12. Takeda, K., B.E. Clausen, T. Kaisho, T. Tsujimura, N.
Terada, I. Forster, and S. Akira. 1999. Enhanced Th1 activity
and development of chronic enterocolitis in mice devoid of
Stat3 in macrophages and neutrophils. Immunity. 10:39–49.
13. Benkhart, E.M., M. Siedlar, A. Wedel, T. Werner, and H.W.
Ziegler-Heitbrock. 2000. Role of Stat3 in lipopolysaccha-
ride-induced IL-10 gene expression. J. Immunol. 165:1612–
1617.
14. Kuhn, R., J. Lohler, D. Rennick, K. Rajewsky, and W.
Muller. 1993. Interleukin-10-deficient mice develop chronic
enterocolitis. Cell. 75:263–274.
15. Costa-Pereira, A.P., S. Tininini, B. Strobl, T. Alonzi, J.F.
Schlaak, H. Is’harc, I. Gesualdo, S.J. Newman, I.M. Kerr,
and V. Poli. 2002. Mutational switch of an IL-6 response to
an interferon-gamma-like response. Proc. Natl. Acad. Sci.
USA. 99:8043–8047.
16. Hong, F., B. Jaruga, W.H. Kim, S. Radaeva, O.N. El-Assal,
Z. Tian, V.A. Nguyen, and B. Gao. 2002. Opposing roles of
STAT1 and STAT3 in T cell-mediated hepatitis: regulation
by SOCS. J. Clin. Invest. 110:1503–1513.
17. Nakagawa, R., T. Naka, H. Tsutsui, M. Fujimoto, A.
Kimura, T. Abe, E. Seki, S. Sato, O. Takeuchi, K. Takeda, et
al. 2002. SOCS-1 participates in negative regulation of LPS
responses. Immunity. 17:677–687.
18. Yoo, J.Y., D.L. Huso, D. Nathans, and S. Desiderio. 2002.
Specific ablation of Stat3beta distorts the pattern of Stat3-
responsive gene expression and impairs recovery from endo-
toxic shock. Cell. 108:331–344.
19. Ardeshna, K.M., A.R. Pizzey, S. Devereux, and A. Khwaja.
2000. The PI3 kinase, p38 SAP kinase, and NF-kappaB sig-
nal transduction pathways are involved in the survival and
maturation of lipopolysaccharide-stimulated human mono-
cyte-derived dendritic cells. Blood. 96:1039–1046.
20. Jacobs, A.T., and L.J. Ignarro. 2001. Lipopolysaccharide-
induced expression of interferon-beta mediates the timing of
inducible nitric-oxide synthase induction in RAW 264.7
macrophages. J. Biol. Chem. 276:47950–47957.
21. Doyle, S., S. Vaidya, R. O’Connell, H. Dadgostar, P. Demp-
sey, T. Wu, G. Rao, R. Sun, M. Haberland, R. Modlin, and
G. Cheng. 2002. IRF3 mediates a TLR3/TLR4-specific
antiviral gene program. Immunity. 17:251–263.
22. Koni, P.A., S.K. Joshi, U.A. Temann, D. Olson, L. Burkly,
and R.A. Flavell. 2001. Conditional vascular cell adhesion
molecule 1 deletion in mice: impaired lymphocyte migration
to bone marrow. J. Exp. Med. 193:741–754.
23. Novak, A., C. Guo, W. Yang, A. Nagy, and C.G. Lobe.
2000. Z/EG, a double reporter mouse line that expresses en-
hanced green fluorescent protein upon Cre-mediated exci-
sion. Genesis. 28:147–155.
24. Braet, F., R. De Zanger, T. Sasaoki, M. Baekeland, P. Jans-
sens, B. Smedsrod, and E. Wisse. 1994. Assessment of a
method of isolation, purification, and cultivation of rat liver
sinusoidal endothelial cells. Lab. Invest. 70:944–952.
25. Poltorak, A., X. He, I. Smirnova, M.Y. Liu, C. Van Huffel,
X. Du, D. Birdwell, E. Alejos, M. Silva, C. Galanos, et al.
1998. Defective LPS signaling in C3H/HeJ and C57BL/
10ScCr mice: mutations in Tlr4 gene. Science. 282:2085–
2088.
26. Qureshi, S.T., L. Lariviere, G. Leveque, S. Clermont, K.J.
Moore, P. Gros, and D. Malo. 1999. Endotoxin-tolerant
mice have mutations in Toll-like receptor 4 (Tlr4). J. Exp.
Med. 189:615–625.
27. Amacher, D.E. 1998. Serum transaminase elevations as indi-
cators of hepatic injury following the administration of drugs.
Regul. Toxicol. Pharmacol. 27:119–130.
28. Knolle, P.A., T. Germann, U. Treichel, A. Uhrig, E.
Schmitt, S. Hegenbarth, A.W. Lohse, and G. Gerken. 1999.
Endotoxin down-regulates T cell activation by antigen-pre-
senting liver sinusoidal endothelial cells. J. Immunol. 162:
1401–1407.
29. Kobayashi, M., M.N. Kweon, H. Kuwata, R.D. Schreiber,
H. Kiyono, K. Takeda, and S. Akira. 2003. Toll-like recep-
tor-dependent production of IL-12 p40 causes chronic en-
terocolitis in myeloid cell-specific Stat3-deficient mice. J.
Clin. Invest. 111:1297–1308.
30. Berlato, C., M.A. Cassatella, I. Kinjyo, L. Gatto, A.
Yoshimura, and F. Bazzoni. 2002. Involvement of suppressor
of cytokine signaling-3 as a mediator of the inhibitory effects
of IL-10 on lipopolysaccharide-induced macrophage activa-
tion. J. Immunol. 168:6404–6411.
31. Salkowski, C.A., G. Detore, R. McNally, N. van Rooijen,
and S.N. Vogel. 1997. Regulation of inducible nitric oxide
synthase messenger RNA expression and nitric oxide pro-
duction by lipopolysaccharide in vivo: the roles of macro-
phages, endogenous IFN-gamma, and TNF receptor-1-
mediated signaling. J. Immunol. 158:905–912.